The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Search
Advanced search
OR
Browse
Search
Volume 132, Issue 13
Displaying 1-8 of 8 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Obituary
Seminar for Medical Education
Case Reports
  • Acceptance of Pregnancy in Pemphigus Patients
    Toru Kimitsu, Maiko Toyoki, Etsuko Komiyama, Hitoshi Tsuchihashi, Yusu ...
    2022 Volume 132 Issue 13 Pages 2841-2844
    Published: December 20, 2022
    Released on J-STAGE: December 20, 2022
    DOIhttps://doi.org/10.14924/dermatol.132.2841
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    We report two pemphigus patients who became during treatment; in both cases, the pregnancy and delivery proceeded without worsening of symptoms. Because pemphigus is a disease that usually affects women in their 4th to 6th decades, there have been few reports of pregnancy and childbirth. We investigated the effects of treatment and childbirth in 8 Japanese pemphigus patients, including our own cases. All the patients received prednisolone 6 to 20 mg/day. In 4 cases, neonatal pemphigus occurred but did not correlated with maternal antibody titer or treatment. We also present a draft of criteria for acceptance of pregnancy in patients with pemphigus; it is based on the acceptance, management, and treatment of pregnancies complicated by SLE.

    View full abstract
    Download PDF (318K)
Review
  • Update on the Safety of Tacrolimus Ointment for Atopic Dermatitis - Carcinogenic and Skin Infection Risks, Applications for Pediatrics, Pregnant and Nursing Mothers
    Hidemi Nakagawa, Hidehisa Saeki, Mamitaro Ohtsuki
    2022 Volume 132 Issue 13 Pages 2845-2855
    Published: December 20, 2022
    Released on J-STAGE: December 20, 2022
    DOIhttps://doi.org/10.14924/dermatol.132.2845
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    The package insert for tacrolimus ointment (Protopic® 0.1% ointment, 0.03% ointment) has been reviewed and revised based on the collected high-evidence safety data from both Japanese and foreign epidemiological studies. The risk of carcinogenicity has been removed from the warning, and the contraindication for its use in pregnant women has also been removed. Therefore, tacrolimus ointment can now be used for pregnant and lactating women under the physician's careful supervision. Epidemiological data indicate that the long-term use of tacrolimus ointment is unlikely to increase the risk of skin infections, and a 10 year follow-up study has confirmed the safety of its use in pediatric patients. Consequently, it is important to provide adequate treatment options after fully explaining the new safety profile of this drug to patients and ensuring their thorough understanding.

    View full abstract
    Download PDF (485K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top